Acétate d'Enfuvirtide (T-20)
Alias:Fusée
Séquence:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
N ° CAS. : 159519-65-0
Formule moléculaire : C204H301N51O64
Masse moléculaire : 4492
Pureté (CLHP) : 98.0%min.
Apparence : Solide amorphe blanc à blanc cassé
Impureté unique (CLHP) : 0.5%maximum
Composition en acides aminés : ±10% de la théorie
Teneur en peptides (N %) : ≥80,0 %
Teneur en eau (Karl Fischer) : ≤8,0 %
Teneur en trifluoroacétate(PCSI) : ≤12,0 %
MME (ESI) : Cohérent
Équilibre de la masse : 95.0~105,0 %
Noter : Qualité pharmaceutique
Stockage: Fermé, dessous 2 ~ 8℃ conservation
Usage : Option de traitement pour les patients atteints du VIH/SIDA.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (AUBERGE) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
